newsfilter
← Latest News
GlobeNewswire·

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023Presented healthy volunteer study results at